Stemgent® DyLight™488 Rabbit anti-Human/Mouse Oct4 Antibody

Product Overview

Dylight^TM 488 Rabbit anti-Human/Mouse Oct-4 Monoclonal Antibody (clone # C30A3). Oct-4 (Octamer-4) is a homeodomain transcription factor of the POU family (POU5F1) involved in regulation of pluripotency during normal development and is detectable in embryonic stem (ES) and germ cells. Its expression is associated with an undifferentiated phenotype and tumors. In fact, gene knockdown of Oct4 promotes differentiation, thereby demonstrating a role for this factor in human ES cell self-renewal. As such, it is frequently used as a marker for undifferentiated ES cells or iPS (induced pluripotent stem) cells. Oct4 is one of the four key transcription factors (Oct4, Sox2, c-Myc, and KLF4) used to reprogram mouse and human fibroblasts to a pluripotent state as well as generate patient-specific iPS cells(1-5).

References

1. Looijenga, L.H., Stoop, H., de Leeuw, H.P., de Gouveia Brazao, C.A., Gillis, A.J., van Roozendaal, K.E., van Zoelen, E.J., Weber, R.F., Wolffenbuttel, K.P., van Dekken, H., Honecker, F., Bokemeyer, C., Perlman, E.J., Schneider, D.T., Kononen, J., Sauter, G., Oosterhuis, J.W. (2003) POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 63: 2244-50.
2. Zaehres, H., Lensch, M.W., Daheron, L., Stewart, S.A., Itskovitz-Eldor, J., Daley, G.Q. (2005) High-efficiency RNA interference in human embryonic stem cells. Stem Cells 23: 299-305.
3. Takahashi, K., Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-76.
4. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-72.
5. Park, I.H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M.W., Cowan, C., Hochedlinger, K., Daley, G.Q. (2008) Disease-specific induced pluripotent stem cells. Cell 134: 877-86.